摘要
社区获得性肺炎(CAP)是临床医生面临的艰巨挑战之一。CAP严重程度分级是患者选择恰当的治疗场所及合理抗生素治疗的基础,故早期识别、全面评估CAP严重程度具有重要意义。使用临床评分系统和/或生物标志物对需要住院治疗或入住重症监护病房(ICU)的高危患者进行早期评估并积极干预可改善生存期并实现更有效的医疗资源分配。本文对近年不同评分系统及生物标志物在CAP患者预后中评估作用的研究进展进行综述。
Community-acquired pneumonia(CAP)is one of the major challenges faced by clinicians.CAP severity grading is the basis for patients to choose appropriate treatment sites and reasonable antibiotic treatment,so it is of great significance to identify and assess comprehensively the severity of CAP at an early stage.Early assessment and active intervention of high-risk patients requiring hospitalization or admission to the intensive care unit(ICU)using clinical scoring systems and/or biomarkers can improve the survival and achieve more effective allocation of medical resources.This article reviews the recent progress in the evaluation of different scoring systems and biomarkers in the prognosis of patients with CAP.
作者
王丽娜
姜春燕
WANG Lina;JIANG Chunyan(Health Care Center,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)
出处
《中国全科医学》
CAS
北大核心
2020年第14期1711-1716,共6页
Chinese General Practice